SCHEMBL14940729

SCHEMBL14940729

CCOC(=O)c1ccc(CNC(=O)OC(C)(C)C)c(F)c1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RPS6KA1 Q15418 1/20 0.41
KCNA5 P22460 1/20 0.39
TSHR P16473 2/20 0.39
NPSR1 Q6W5P4 2/20 0.38
TP53 P04637 2/20 0.38
HTT P42858 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
ADORA3 P0DMS8 2/20 0.38
ADORA2A P29274 2/20 0.38
KDM4A O75164 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
MAPT P10636 2/20 0.37
KDM4E B2RXH2 1/20 0.37
CA12 O43570 2/20 0.37
CA1 P00915 2/20 0.37
CA2 P00918 2/20 0.37
CA9 Q16790 2/20 0.37
CA7 P43166 1/20 0.37
CA14 Q9ULX7 1/20 0.37
CRHBP P24387 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12231435 0.88 ATR (0.42) RPS6KA1KCNA5KDM4AL3MBTL1KDM4E
SCHEMBL14940927 0.84 KCNA5 (0.42) RPS6KA1KCNA5HTTKDM4AL3MBTL1
SCHEMBL10012827 0.84 TSHR (0.43) RPS6KA1KCNA5TSHRNPSR1TDP1
SCHEMBL12234545 0.80 RPS6KA1 (0.43) RPS6KA1KCNA5TDP1KDM4AL3MBTL1
SCHEMBL29726426 0.78 RPS6KA1 (0.42) RPS6KA1KCNA5KDM4AL3MBTL1KDM4E
SCHEMBL19085509 0.78 RPS6KA1 (0.47) RPS6KA1KCNA5KDM4AL3MBTL1CA12
SCHEMBL20095633 0.78 RPS6KA1 (0.42) RPS6KA1KCNA5HTTKDM4AL3MBTL1
SCHEMBL24745641 0.76 L3MBTL1 (0.38) KCNA5NPSR1ADORA3ADORA2AKDM4A
SCHEMBL27413370 0.76 L3MBTL1 (0.43) KCNA5NPSR1TDP1KDM4AL3MBTL1
SCHEMBL31431692 0.75 RPS6KA1 (0.45) RPS6KA1KCNA5KDM4AL3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140309192-A1 MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC, 2014-10-16 US disclosed
EP-2776407-A1 MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO Arena Pharmaceuticals, Inc. (US) 2014-09-17 EP disclosed
WO-2013070657-A1 MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2013-05-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140309192-A1 MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO MRGPRX1, MRGPRX2, AGTR1 RPS6KA1 2071/4885KCNA5 906/4885TSHR 245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.